Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • World
  • Mid-East
  • Europe
  • Americas
  • Asia Pacific
  • Africa
  • Syrian Crisis
  • Islamophobia

EU med watchdog approves US-based Novavax COVID-19 jab

by French Press Agency - AFP

The Hague Dec 20, 2021 - 4:47 pm GMT+3
An exterior view of the European Medicines Agency, EMA, in Amsterdam's business district, Netherlands, April 20, 2021. (AP Photo)
An exterior view of the European Medicines Agency, EMA, in Amsterdam's business district, Netherlands, April 20, 2021. (AP Photo)
by French Press Agency - AFP Dec 20, 2021 4:47 pm
RECOMMENDED
World leaders from G7 and invited countries pose for a family photo, during the G7 Leaders' Summit in Hiroshima, Japan, May 20, 2023. (AFP Photo)

G-7 urges China to respect Taiwan, press Russia to end Ukraine war

group-of-seven

The COVID-19 vaccine by United States-based Novavax was approved Monday by Europe's medicines watchdog. The jab uses a more conventional technology that the biotech firm hopes will reduce vaccine hesitancy.

The protein-based vaccine of the kind used around the world to protect against many childhood illnesses is the fifth coronavirus shot authorized for use in the European Union.

"EMA has recommended granting a conditional marketing authorization for Novavax's COVID-19 vaccine Nuvaxovid to prevent COVID-19 in people from 18 years of age," the European Medicines Agency (EMA) said in a statement.

"After a thorough evaluation, EMA's human medicines committee concluded by consensus that the data on the vaccine were robust and met the EU criteria for efficacy, safety and quality," the Amsterdam-based agency said.

Two main clinical trials – one in Britain and the other in the U.S. and Mexico and involving more than 45,000 people in total, showed between 89% to 90% efficacy in reducing the number of symptomatic COVID-19 cases, the EMA said.

But the watchdog said the clinical studies involved the original COVID-19 strain and some variants of concern such as alpha and beta, which were "the most common viral strains circulating when the studies were ongoing."

"There is currently limited data on the efficacy of Nuvaxovid against other variants of concern, including omicron," it said.

'Well-understood platform'

Monday's approval is also a boost for the Maryland company, whose jab has been plagued by delays.

The European Union has already signed a deal to buy up to 200 million doses of the two-shot vaccine pending the EMA's approval.

Chief executive Stanley Erck said the firm "looks forward to providing an additional vaccine option in Europe, built on a proven, well-understood technology platform."

The vaccine "may help address major obstacles to global vaccination, including global distribution challenges and vaccine hesitancy," Erck added.

All vaccines work by teaching the body's immune system to attack the coronavirus, but they do it in different ways.

Novavax's so-called protein subunit technology is already tried and tested, having been used for decades to vaccinate people against diseases including hepatitis B and whooping cough.

It also means it does not have to be stored in ultra-low temperatures, potentially giving it a logistical edge over some other jabs.

'Production problems'

Novavax uses tiny, lab-made fragments of a protein found on the surface of the coronavirus spike.

When injected, these trigger a reaction by the immune system, so that if it later comes into contact with the COVID virus, it knows to attack it.

By contrast, the Pfizer-BioNTech and Moderna vaccines have dominated the global COVID response using pioneering, but hitherto largely untested Messenger RNA (mRNA) technology.

They use a molecule of genetic material known as RNA to deliver a message to cells to produce the spike protein themselves. The body's immune system then learns to recognize the protein and attack it.

The viral vector approach used by AstraZeneca and Johnson & Johnson works on a similar principle, but delivers the genetic message via a version of the common cold adenovirus as a "vector."

Rare but serious side effects of heart inflammation have been reported with the mRNA vaccines, and blood clots with the viral vector vaccines.

But Novavax has struggled with months of delays amid what a group of MEPs recently called "production problems."

Indonesia and the Philippines have already approved the Novavax jab, while Japan has agreed to buy 150 million doses.

Novavax says it has also filed for approval in Britain, India, Australia, New Zealand, Canada, and with the World Health Organization.

The company has also said it is "evaluating its vaccine against the omicron variant" and working on an omicron-specific version.

RECOMMENDED
World leaders from G7 and invited countries pose for a family photo, during the G7 Leaders' Summit in Hiroshima, Japan, May 20, 2023. (AFP Photo)

G-7 urges China to respect Taiwan, press Russia to end Ukraine war

group-of-seven
  • shortlink copied
  • RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 outbreak coronavirus european union novavax
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    An amateur photographer Vincent Cornelissen captures a bean goose flying upside down. (Photo from Instagram @b0unce1971)

    It is showing off: Photographer captures goose flying upside down

    ANIMALS-ARCHIVES
    A crude oil tanker sails in the Bosporus, on its way to the Mediterranean Sea, in Istanbul, Türkiye, Dec. 11, 2022. (Reuters Photo)

    Türkiye registers better-than-expected current account gap

    current-account-balance

    Accumulated tension of hundreds of years moved Anatolia by 3m

    Harold-Tobin

    Istanbul's consulate chronicles: Sudhi Choudhary, Consul General of India

    SUDHI-CHOUDHARY
    No Image
    All paws on deck! Cat sails high seas with caring crew
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021